Skip to main content

Table 3 AEs leading to treatment discontinuation in three or more patients

From: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

AE, n (%)

Daclizumab 150 mg SC

(N = 410)

Any AE leading to treatment discontinuation

48 (12)

 Investigations

19 (5)

  Increased ALT

11 (3)

  Increased AST

5 (1)

  Increased hepatic enzyme

4 (<1)

 Skin and subcutaneous tissue disorders

12 (3)

  Allergic dermatitis

3 (<1)

 Gastrointestinal disorders

4 (<1)

  Colitis

3 (<1)

 Hepatobiliary disorders

4 (<1)

 Infections and infestations

4 (<1)

  1. AE Adverse event, ALT Alanine transaminase, AST Aspartate transaminase, SC Subcutaneous